146 related articles for article (PubMed ID: 3700343)
1. Combination therapy with lecithin and ergoloid mesylates for Alzheimer's disease.
Jenike MA; Albert MS; Heller H; LoCastro S; Gunther J
J Clin Psychiatry; 1986 May; 47(5):249-51. PubMed ID: 3700343
[TBL] [Abstract][Full Text] [Related]
2. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
Jenike MA; Albert MS; Heller H; Gunther J; Goff D
J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997
[TBL] [Abstract][Full Text] [Related]
3. Lack of efficacy of hydergine in patients with Alzheimer's disease.
Thompson TL; Filley CM; Mitchell WD; Culig KM; LoVerde M; Byyny RL
N Engl J Med; 1990 Aug; 323(7):445-8. PubMed ID: 2082953
[TBL] [Abstract][Full Text] [Related]
4. Failure of long term high-dose lecithin to retard progression of early-onset Alzheimer's disease.
Heyman A; Schmechel D; Wilkinson W; Rogers H; Krishnan R; Holloway D; Schultz K; Gwyther L; Peoples R; Utley C
J Neural Transm Suppl; 1987; 24():279-86. PubMed ID: 3479525
[TBL] [Abstract][Full Text] [Related]
5. Comparison of therapeutic response to long-term treatment with lecithin versus piracetam plus lecithin in patients with Alzheimer's disease.
Smith RC; Vroulis G; Johnson R; Morgan R
Psychopharmacol Bull; 1984; 20(3):542-5. PubMed ID: 6433396
[No Abstract] [Full Text] [Related]
6. Ergoloid mesylates vs. Alzheimer's: the latest round.
Walker C
Geriatrics; 1990 Dec; 45(12):22, 24. PubMed ID: 2253892
[No Abstract] [Full Text] [Related]
7. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
8. Ergoloid mesylates and ECT.
Sachs GS; Gelenberg AJ; Bellinghausen B; Wojcik J; Falk WE; Farhadi AM; Jenike M
J Clin Psychiatry; 1989 Mar; 50(3):87-90. PubMed ID: 2647711
[TBL] [Abstract][Full Text] [Related]
9. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease.
Wettstein A
Ann Neurol; 1983 Feb; 13(2):210-2. PubMed ID: 6830183
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
[TBL] [Abstract][Full Text] [Related]
11. Double-blind clinical and psychologic study of ergoloid mesylates (Hydergine) in subjects with senile mental deterioration.
van Loveren-Huyben CM; Engelaar HF; Hermans MB; van der Bom JA; Leering C; Munnichs JM
J Am Geriatr Soc; 1984 Aug; 32(8):584-8. PubMed ID: 6379022
[TBL] [Abstract][Full Text] [Related]
12. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
Filip V; Kolibás E
J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study.
Demarin V; Podobnik SS; Storga-Tomic D; Kay G
Drugs Exp Clin Res; 2004; 30(1):27-33. PubMed ID: 15134388
[TBL] [Abstract][Full Text] [Related]
14. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study.
Paleacu D; Barak Y; Mirecky I; Mazeh D
Int J Geriatr Psychiatry; 2008 Apr; 23(4):393-400. PubMed ID: 17879256
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
Antuono PG
Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
[TBL] [Abstract][Full Text] [Related]
16. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.
Chatellier G; Lacomblez L
BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926
[TBL] [Abstract][Full Text] [Related]
17. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Greenspan A
Int J Geriatr Psychiatry; 2005 Dec; 20(12):1153-7. PubMed ID: 16315159
[TBL] [Abstract][Full Text] [Related]
18. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
Chiu CC; Su KP; Cheng TC; Liu HC; Chang CJ; Dewey ME; Stewart R; Huang SY
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1538-44. PubMed ID: 18573585
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
20. Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease.
Monji A; Takita M; Samejima T; Takaishi T; Hashimoto K; Matsunaga H; Oda M; Sumida Y; Mizoguchi Y; Kato T; Horikawa H; Kanba S
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):308-11. PubMed ID: 19138715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
